Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy (Q33973488)

From Wikidata

Revision as of 18:52, 30 November 2021 by KrBot (talk | contribs) (‎Set a claim value: title (P1476): Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David A. Isenberg

2

object named as

Isenberg DA

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Ioannou Y

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 July 2000

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1431-1442

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Interferon alfa-2B in chronic lymphatic leukemia of the B-cell type

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Side effects of high-dose interferon therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Systemic lupus erythematosus in a child receiving long-term interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Immunological disorders in C virus chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Mono-arthritis in a chronic hepatitis B patient after alpha-interferon treatment

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Elevated soluble fas production in SLE correlates with HLA status not with disease activity.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Type I interferons

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Cytokine-induced autoimmune disorders

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

The Th1-Th2 model--what relevance to inflammatory arthritis?

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Rheumatic disease following immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Inclusion body myositis and renal cell carcinoma. Report of two cases and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Hepatitis C virus infection and autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Interferon-gamma and host antimicrobial defense: current and future clinical applications

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Immune thrombocytopenia and alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Exacerbations of multiple sclerosis in patients treated with gamma interferon

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Effects of Interferon-γ Therapy on Thyroid Function, T-Lymphocyte Subpopulations and Induction of Autoantibodies

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

Identifiers

10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33973488&oldid=1536717973"